Compare · NNNN vs OCX
NNNN vs OCX
Side-by-side comparison of Anbio Biotechnology (NNNN) and Oncocyte Corporation (OCX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NNNN and OCX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NNNN is the larger of the two at $3.31B, about 22.1x OCX ($149.4M).
- Over the past year, NNNN is up 109.4% and OCX is up 12.4% - NNNN leads by 97.0 points.
- Both names hit the wire about 1 times in the past 4 weeks.
- OCX has more recent analyst coverage (9 ratings vs 0 for NNNN).
- Company
- Anbio Biotechnology
- Oncocyte Corporation
- Price
- $18.03-35.24%
- $3.17+14.03%
- Market cap
- $3.31B
- $149.4M
- 1M return
- -31.17%
- +12.41%
- 1Y return
- +109.41%
- +12.41%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- AMEX
- IPO
- 2025
- News (4w)
- 1
- 1
- Recent ratings
- 0
- 9
Oncocyte Corporation
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation has a strategic collaboration with Gruppo Oncologico del Nord-Ovest of Pisa to evaluate DetermaIO as a biomarker for immunotherapy response in metastatic colorectal cancer; and Echelon Diagnostics, Inc. The company was founded in 2009 and is headquartered in Irvine, California.
Latest NNNN
- SEC Form 6-K filed by Anbio Biotechnology
- SEC Form 6-K filed by Anbio Biotechnology
- Amendment: SEC Form 20-F/A filed by Anbio Biotechnology
- SEC Form 3 filed by new insider Song Suki
- SEC Form 3 filed by new insider Hartzler Nancy
- SEC Form 3 filed by new insider Lau Michael
- SEC Form 3 filed by new insider Tian Chris
- SEC Form 3 filed by new insider Xu Cany
- SEC Form 20-F filed by Anbio Biotechnology
- Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum
Latest OCX
- InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors
- Director Arno Andrew was granted 55,000 shares, increasing direct ownership by 67% to 136,554 units (SEC Form 4)
- Director Silverman Lou was granted 35,000 shares, increasing direct ownership by 2,238% to 36,564 units (SEC Form 4)
- Director Last Andrew J. was granted 35,000 shares, increasing direct ownership by 776% to 39,509 units (SEC Form 4)
- Oncocyte Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Oncocyte Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville
- Medicare Boosts Reimbursement for Oncocyte's Flagship Technology
- SEC Form DEFA14A filed by Oncocyte Corporation
- SEC Form DEF 14A filed by Oncocyte Corporation